New drug duo shows promise against Hard-to-Treat lymphoma
NCT ID NCT03198026
First seen Feb 23, 2026 · Last updated May 14, 2026 · Updated 9 times
Summary
This study tests whether combining two drugs—obinutuzumab and ibrutinib—can shrink or eliminate slow-growing non-Hodgkin's lymphoma in people who haven't been treated before. About 30 adults with various stages of the disease will receive the drugs as their first therapy. The goal is to see how many patients achieve a complete or partial response, meaning their cancer significantly reduces or disappears.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INDOLENT NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.